On August 5, Twist Bioscience Corp rose 6.59% in regular trading, trading at $110.92/share, with turnover of $45.24 million.

On the news front, the company recently reported fiscal Q3 results with revenue of $118.4 million, up 23.2% year-over-year, beating analyst estimates of $114.5 million. More critically, the company raised its full-year revenue guidance to $456-$457 million and projected Q4 revenue of $123-$124 million, substantially above the FactSet consensus estimate of $117.4 million. While Q3 EPS of $(0.56) missed the consensus estimate of $(0.51) and marked a swing from year-ago earnings of $0.33 per share, the strong revenue growth momentum and above-consensus forward guidance have continued to bolster investor confidence in the company's business expansion outlook, driving sustained stock price recovery following initial post-earnings selling pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)